Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Colorectal cancer AND KRAS, C-K-RAS, 3845, P01116, NS3, KI-RAS, KRAS2, K-RAS4A, K-RAS2A, K-RAS4B, KRAS1, K-RAS2B, RASK2 AND Clinical Outcome
203 results:

  • 1. Complete remission in a pretreated, microsatellite-stable,
    He L; Li H; Wang Y; Li W; Gao L; Xu B; Hu J; He P; Pu W; Sun G; Wang Z; Han Q; Liu B; Chen H
    Front Immunol; 2024; 15():1354613. PubMed ID: 38617840
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Nuclear pore protein POM121 regulates subcellular localization and transcriptional activity of PPARγ.
    Yu Y; Farooq MS; Eberhart Meessen S; Jiang Y; Kato D; Zhan T; Weiss C; Seger R; Kang W; Zhang X; Yu J; Ebert MPA; Burgermeister E
    Cell Death Dis; 2024 Jan; 15(1):7. PubMed ID: 38177114
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Feasibility of [
    Bae SW; Wang J; Georgiou DK; Wen X; Cohen AS; Geng L; Tantawy MN; Manning HC
    Tomography; 2023 Feb; 9(2):497-508. PubMed ID: 36961000
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Localization and density of tertiary lymphoid structures associate with molecular subtype and clinical outcome in colorectal cancer liver metastases.
    Zhang C; Wang XY; Zuo JL; Wang XF; Feng XW; Zhang B; Li YT; Yi CH; Zhang P; Ma XC; Chen ZM; Ma Y; Han JH; Tao BR; Zhang R; Wang TQ; Tong L; Gu W; Wang SY; Zheng XF; Yuan WK; Kan ZJ; Fan J; Hu XY; Li J; Zhang C; Chen JH
    J Immunother Cancer; 2023 Feb; 11(2):. PubMed ID: 36759015
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Genomic Landscape of Primary Tumor Site and clinical outcome for Patients with Metastatic colorectal cancer Receiving Standard-of-Care Chemotherapy.
    Mizukami T; Takahashi M; Sunakawa Y; Yuki S; Kagawa Y; Takashima A; Kato K; Hara H; Denda T; Yamamoto Y; Shiozawa M; Oki E; Okamoto W; Yoshino T; Eguchi Nakajima T
    Target Oncol; 2022 May; 17(3):343-353. PubMed ID: 35524872
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. SPATA18 Expression Predicts Favorable clinical outcome in colorectal cancer.
    Sugimura-Nagata A; Koshino A; Nagao K; Nagano A; Komura M; Ueki A; Ebi M; Ogasawara N; Tsuzuki T; Kasai K; Takahashi S; Kasugai K; Inaguma S
    Int J Mol Sci; 2022 Mar; 23(5):. PubMed ID: 35269894
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Tumor stromal nicotinamide N-methyltransferase overexpression as a prognostic biomarker for poor clinical outcome in early-stage colorectal cancer.
    Ogawa M; Tanaka A; Namba K; Shia J; Wang JY; Roehrl MHA
    Sci Rep; 2022 Feb; 12(1):2767. PubMed ID: 35177765
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Identification and functional analysis of lncRNAs and mRNAs between tumorigenesis and metastasis in CRC.
    Liu H; Tian Y; Li J; Zhang G; Liu Q; Yang M; Yue L; Cao Q; Zhang G; Cheng Y; Kong N; Fang L; Li S; Sun Q
    Aging (Albany NY); 2021 Dec; 13(24):25859-25885. PubMed ID: 34954693
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. A five-year follow up study of stage I-IV of rectal cancer with an emphasis on epidermal growth factor over-expression.
    Kozłowska-Geller MA; Lewitowicz P; Głuszek SZ
    Pol J Pathol; 2021; 72(2):124-129. PubMed ID: 34706519
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. A Possible Distinct Molecular Subtype (Quintuple-Wildtype) of Metastatic colorectal cancer in First-Line Anti-EGFR Therapy with Cetuximab Plus FOLFIRI - Palliative Precision Therapy and a Multidisciplinary Treatment Approach: Interim Analysis of the IVOPAK II Trial with Early Results.
    Wein A; Stoehr R; Kersting S; Siebler J; Merkel S; Busse D; Wolff K; Ostermeier N; Neufert C; Vitali F; Eckstein M; Roth JP; Anhut P; Schreiner W; Uder M; Hartmann A; Neurath MF; Grützmann R
    Oncology; 2022; 100(1):1-11. PubMed ID: 34670215
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Genome-Derived Classification Signature for Ampullary Adenocarcinoma to Improve clinical cancer Care.
    Chakraborty S; Ecker BL; Seier K; Aveson VG; Balachandran VP; Drebin JA; D'Angelica MI; Kingham TP; Sigel CS; Soares KC; Vakiani E; Wei AC; Chandwani R; Gonen M; Shen R; Jarnagin WR
    Clin Cancer Res; 2021 Nov; 27(21):5891-5899. PubMed ID: 34433650
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Circulating tumor DNA sequencing in colorectal cancer patients treated with first-line chemotherapy with anti-EGFR.
    Lim Y; Kim S; Kang JK; Kim HP; Jang H; Han H; Kim H; Kim MJ; Lee KH; Ryoo SB; Park JW; Jeong SY; Park KJ; Kang GH; Han SW; Kim TY
    Sci Rep; 2021 Aug; 11(1):16333. PubMed ID: 34381078
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Identified a disintegrin and metalloproteinase with thrombospondin motifs 6 serve as a novel gastric cancer prognostic biomarker by bioinformatics analysis.
    Zhu YZ; Liu Y; Liao XW; Luo SS
    Biosci Rep; 2021 Apr; 41(4):. PubMed ID: 33851708
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Improving selection of patients with metastatic colorectal cancer to benefit from cetuximab based on KIR genotypes.
    Manzanares-Martin B; Cebrián Aranda A; Del Puerto-Nevado L; González R; Solanes S; Gómez-España MA; García-Foncillas J; Aranda E
    J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33833048
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Comprehensive functional genomic analyses link APC somatic mutation and mRNA-miRNA networks to the clinical outcome of stage-III colorectal cancer patients.
    Chiang SF; Huang HH; Tsai WS; Chin-Ming Tan B; Yang CY; Huang PJ; Yi-Feng Chang I; Lin J; Lu PS; Chin E; Liu YH; Yu JS; Chiang JM; Hung HY; You JF; Liu H
    Biomed J; 2022 Apr; 45(2):347-360. PubMed ID: 35550340
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. Long-term clinical outcome of Trastuzumab and Lapatinib for HER2-positive Metastatic colorectal cancer.
    Tosi F; Sartore-Bianchi A; Lonardi S; Amatu A; Leone F; Ghezzi S; Martino C; Bencardino K; Bonazzina E; Bergamo F; Fenocchio E; Martinelli E; Troiani T; Siravegna G; Mauri G; Torri V; Marrapese G; Valtorta E; Cassingena A; Cappello G; Bonoldi E; Vanzulli A; Regge D; Ciardiello F; Zagonel V; Bardelli A; Trusolino L; Marsoni S; Siena S
    Clin Colorectal Cancer; 2020 Dec; 19(4):256-262.e2. PubMed ID: 32919890
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Determination of the UGT1A1 polymorphism as guidance for irinotecan dose escalation in metastatic colorectal cancer treated with first-line bevacizumab and FOLFIRI (PURE FIST).
    Tsai HL; Huang CW; Lin YW; Wang JH; Wu CC; Sung YC; Chen TL; Wang HM; Tang HC; Chen JB; Ke TW; Tsai CS; Huang HY; Wang JY
    Eur J Cancer; 2020 Oct; 138():19-29. PubMed ID: 32829105
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. Prognostic value of molecular biomarkers in patients with metastatic colorectal cancer: a real-world study.
    García-Alfonso P; García-González G; Gallego I; Peligros MI; Ortega L; Torres Pérez-Solero G; Sandoval C; Muñoz Martin A; Blanco Codesido M; Calvo Ferrándiz A; Martin M
    Clin Transl Oncol; 2021 Jan; 23(1):122-129. PubMed ID: 32519179
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. Blocking histone methyltransferase SETDB1 inhibits tumorigenesis and enhances cetuximab sensitivity in colorectal cancer.
    Hou Z; Sun L; Xu F; Hu F; Lan J; Song D; Feng Y; Wang J; Luo X; Hu J; Wang G
    Cancer Lett; 2020 Sep; 487():63-73. PubMed ID: 32473242
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. The Interleukin 22 Pathway Interacts with Mutant kras to Promote Poor Prognosis in Colon cancer.
    McCuaig S; Barras D; Mann EH; Friedrich M; Bullers SJ; Janney A; Garner LC; Domingo E; Koelzer VH; Delorenzi M; Tejpar S; Maughan TS; West NR; Powrie F
    Clin Cancer Res; 2020 Aug; 26(16):4313-4325. PubMed ID: 32430479
    [TBL] [Abstract] [Full Text] [Related]  


    of 11.